RWM
PTGX icon

Rialto Wealth Management’s Protagonist Therapeutics PTGX Stock Holding History

Rialto Wealth Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$613 Buy
+5
New +$522 ﹤0.01% 1578

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Rialto Wealth Management's PTGX Position: Q2 2026 in Review

Rialto Wealth Management opened a new position in Protagonist Therapeutics (PTGX) in Q2 2026: 5 shares worth $613. The stake represents ﹤0.01% of the portfolio and ranks #1578 among its holdings.

343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Rialto Wealth Management held 5 shares of Protagonist Therapeutics worth $613 as of Q2 2026.
  • Protagonist Therapeutics was a new Rialto Wealth Management position in Q2 2026.
  • Protagonist Therapeutics made up ﹤0.01% of Rialto Wealth Management's portfolio in Q2 2026, its #1578 holding.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Rialto Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.